Peptides Nepal

Posts › Semaglutide vs tirzepatide: the head-to-head trial

Semaglutide vs tirzepatide: the head-to-head trial

Semaglutide vs tirzepatide: the head-to-head trial. What SURMOUNT-5 found, and what it can't tell you.
The trial. Name: SURMOUNT-5. People: 751 adults with obesity, without type 2 diabetes. Length: 72 weeks. Doses: Highest tolerated: tirzepatide 10 or 15 mg, semaglutide 1.7 or 2.4 mg, weekly.
Average body-weight change at 72 weeks. Tirzepatide: −20.2% · about 22.8 kg. Semaglutide: −13.7% · about 15.0 kg.
What it can't tell you. Open-label: people knew which drug they were taking. Funded by Eli Lilly, the maker of tirzepatide. These are averages. Individual results vary widely.
Tirzepatide led on average weight loss in this trial. One trial, read carefully. Save this · Follow @peptidesnepal Education only. Not medical advice.

→ SURMOUNT-5: 751 adults with obesity (no type 2 diabetes), 72 weeks.
→ Tirzepatide: −20.2% average body weight (about 22.8 kg).
→ Semaglutide: −13.7% (about 15.0 kg).
→ Limits: open-label, funded by tirzepatide's maker, and averages hide big individual differences.

📌 Save this before the next "which is better" debate.
📤 Send it to someone comparing the two.

Did the gap surprise you? Yes or no?

Follow @peptidesnepal for more info
Visit our website — link in bio for detailed info like this!

Education only — not medical advice.

Sources

Sources 📚
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025;393(1):26–36. doi:10.1056/NEJMoa2416394

View this post on Instagram →

Related guides

Semaglutide Approved

A GLP-1 receptor agonist: a copy of the gut hormone GLP-1 with a fatty-acid side chain that makes it last about a week.

Tirzepatide Approved

Acts on two gut-hormone receptors: GLP-1 and GIP.